Ontology highlight
ABSTRACT: Background
The present review investigated which findings in vascular imaging techniques can be used to predict clinical outcome and the risk of symptomatic intracerebral hemorrhage (sICH) in patients who underwent intravenous thrombolytic treatment.Methods
Publications were searched, and the inclusion criteria were as follows: (1) published manuscripts, (2) patients with acute ischemic stroke managed with intravenous recombinant tissue plasminogen activator (rtPA), and (3) availability of imaging assessment to determine vessel patency or the regulation of cerebral blood flow prior to, during, and/or after thrombolytic treatment. Clinical outcomes were divided into neurological outcome [National Institutes of Health Stroke Scale (NIHSS) within 7?days] and functional outcome (modified Rankin score in 2-3?months). sICH was defined as rtPA-related intracerebral bleeding associated with any worsening of NIHSS.Results
Thirty-nine articles were selected. Recanalization was associated with improved neurological and functional outcomes (OR?=?7.83; 95% CI, 3.71-16.53; p?ConclusionBrain circulation data before, during, and after thrombolysis may be useful for predicting the clinical outcome. Cerebral arterial recanalization, presence and site of occlusion, and reocclusion are all important in predicting the clinical outcome.
SUBMITTER: Nogueira RC
PROVIDER: S-EPMC4870283 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
Nogueira Ricardo C RC Bor-Seng-Shu Edson E Saeed Nazia P NP Teixeira Manoel J MJ Panerai Ronney B RB Robinson Thompson G TG
Frontiers in neurology 20160518
<h4>Background</h4>The present review investigated which findings in vascular imaging techniques can be used to predict clinical outcome and the risk of symptomatic intracerebral hemorrhage (sICH) in patients who underwent intravenous thrombolytic treatment.<h4>Methods</h4>Publications were searched, and the inclusion criteria were as follows: (1) published manuscripts, (2) patients with acute ischemic stroke managed with intravenous recombinant tissue plasminogen activator (rtPA), and (3) avail ...[more]